High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays

Breast Cancer Research and Treatment
Christopher SchroederMichael Bonin

Abstract

Breast cancer is the most frequent form of carcinoma in European females (incidence 65 per 100,000). In about 10% of all cases, pedigree analysis predicts a hereditary breast-ovarian cancer syndrome (HBOC) to be causative for the disease. Frequently, mutations in two genes, BRCA1 (Chr. 17q21) and BRCA2 (Chr. 13q12), are associated with HBOC. In females, mutations in these genes result in a lifetime risk of 80-85% for breast cancer and 54% (BRCA1) or 23% (BRCA2) for ovarian cancer. Current genetic diagnostic tools for BRCA1 and BRCA2 remain laborious and expensive. Here, we present the first oligonucleotide resequencing microarray covering the complete coding sequence of both genes. In total, 36 previously characterized DNAs were resequenced; all 11 patients with single-nucleotide mutations and, due to a special mutational design, eight patients with heterozygous deletions were detected correctly. In total, 47 different single-nucleotide variants (SNVs) were found. A newly developed software, SeqC, reduced the number of ambiguous calls with the help of a statistical module comparing the acquired data to an online-database. SeqC improved the average call rate to 99% (GSeq: 97%) and reduced time and efforts for manual analysis. Se...Continue Reading

References

Sep 8, 2000·BMJ : British Medical Journal·K McPhersonJ M Dixon
Nov 3, 2001·Genome Research·D J CutlerA Chakravarti
Oct 25, 2003·Science·Mary-Claire KingUNKNOWN New York Breast Cancer Study Group
May 5, 2004·Genome Research·Anirban MaitraAravinda Chakravarti
Aug 27, 2005·Investigative Ophthalmology & Visual Science·Md Nawajes A MandalRadha Ayyagari
Feb 22, 2007·Current Molecular Medicine·John K Cowell, Lesleyann Hawthorn
May 2, 2007·International Journal of Cancer. Journal International Du Cancer·M J Bermejo-PérezA Llanos-Méndez
Dec 19, 2007·The Breast Journal·Henry T LynchJane F Lynch
Feb 9, 2008·Clinical Chemistry·Stephan WaldmüllerThomas Scheffold
Feb 19, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Henrike E Karim-KosJan Willem W Coebergh
Jun 26, 2008·Human Genetics·Philippe M CampeauMarc D Tischkowitz
Oct 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew D SpearmanAmanda Ewart Toland
Oct 11, 2008·Nature Biotechnology·Jay Shendure, Hanlee Ji

❮ Previous
Next ❯

Citations

Jul 19, 2011·Genome Research·John F ThompsonPatrice M Milos
Aug 10, 2012·The Journal of Molecular Diagnostics : JMD·Hilmi OzcelikKathy Siminovitch
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Tom WalshMary-Claire King
Oct 11, 2016·Pathology Oncology Research : POR·Leila SabourSaeid Ghorbian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.